The Quigley Corporation to Announce Third Quarter Results and Host Audio Web Cast

DOYLESTOWN, Pa., Nov. 6 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY - News), www.quigleyco.com, today announced it will issue its third quarter results at 8:30 AM (ET) on Thursday, November 12, 2009. Ted Karkus, Chairman and CEO, will provide a Company overview, including a review of activities and third quarter results, on a conference call which will be web cast live on The Quigley Corporation's web site, (www.quigleyco.com), at 11:00 AM (ET) that morning.A replay of the conference call will be available for 30 days on the Company web site.About The Quigley CorporationThe Quigley Corporation (Nasdaq: QGLY - News; ...
Click here to read the whole Article (external link)

QUIGLEY CORP Files SEC form 8-K, Change in Directors or Principal Officers

Show all filings for QUIGLEY CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for QUIGLEY CORP 22-Oct-2009Change in Directors or Principal Officers Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intende...
Click here to read the whole Article (external link)

QUIGLEY CORP Financials

PERIOD ENDING30-Jun-0931-Mar-0931-Dec-0830-Sep-08Total Revenue1,748  3,987  6,779  6,354  Cost of Revenue1,457  1,634  3,915  2,272  Gross Profit291  2,352  2,863  4,082  Operating ExpensesResearch Development386  248  612  955  Selling General and Administrative4,535  4,314  4,251  2,313  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(4,629)(2,210)(2,000)814  Income from Continuing OperationsTotal Other Income/Expenses Net4  11  34  65  Earnings Before Interest And Taxes(4,625)(2,199)(1,965)879  Interest Expense -   -   -   -  Income Before Tax(4,625)(2,199)(1,965)879  Income Tax Expense -   -   -   -  Minority Interest -   -   -   -  Net Income From Continuing Ops(4,625)(2,199)(1,965)879  Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   -   ...
Click here to read the whole Article (external link)

The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update

DOYLESTOWN, Pa., Nov. 11 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY - News), www.quigleyco.com today announced it will host a conference call in which Ted Karkus, Chairman and CEO, will provide a Company overview including a review of activities, third quarter results and Q&A. The conference call will be web cast live on The Quigley Corporation's web site, (www.quigleyco.com), at 11:00 AM (ET) on Thursday, November 12, 2009. The Company will issue its third quarter results at 8:30 AM (ET) that day.Participants wishing to ask questions may access the live call by dialing (877) 217 - 6026. A replay of the conference call will be available for 30 days on the Company web site.About The Quigley CorporationThe Quigley Corporation (Nasdaq: QGLY - ...
Click here to read the whole Article (external link)

The Quigley Corporation Reports Third Quarter 2009 Results

DOYLESTOWN, Pa., Nov. 12 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY - News) www.quigleyco.com today reported net sales of $5.0 million for the three months ended September 30, 2009, compared to net sales of $6.4 million for the three months ended September 30, 2008. The Company generated net income for the three months ended September 30, 2009, of $1.2 million, or $0.09 per share, compared to net income of $879,000, or $0.07 per share, for the three months ended September 30, 2008.Results for the third quarter of 2009 compared to the third quarter of 2008 primarily reflect a decrease in net sales of $1.4 million and a corresponding decrease of $467,000 in gross profit. These decreases were offset by reductions of $236,000 in sales, marketing and administration expenses and $614,000 in research and development costs. The decrease in these costs was principally due to reduced personnel costs, and a reduction in clinical study related costs incurred as a result of the completion of the QR-333 Diabetic Neuropathy Phase IIb study, results of which were previously reported on July 22, 2009.For the nine months ended September 30, 2009, net sales were $10.7 million, compared to net sales of $13.7 million, for the nine months ended September 30, 2008.The net loss for the nine months en...
Click here to read the whole Article (external link)

Q3 2009 Quigley Earnings Release - 08:30 am ET

Earnings Announcements for Thursday, November 12CompanySymbolTimeConferenceCall3i Group plcIII.LBefore Market Open3SBIO INCSSRXAfter Market CloseListenA.D.A.M., Inc.ADAMTime Not SuppliedListenA2A SpAA2A.MITime Not SuppliedAcciona, S.A.ACXIF.PKBefore Market OpenACSM S P AACS.MITime Not SuppliedADDUS HOMECARE CORPADUSBefore Market OpenListenAdvanSource Biomaterials CorporationASBTime Not SuppliedADVANTAGE OIL & GAS LTDAAVAfter Market CloseAECOMACMBefore Market OpenListenAEFFE SPAAEF.MITime Not SuppliedAEGON N.V.AEGOF.PK01:30 am ETAFC Enterprises, Inc.AFCEAfter Market CloseListenAG GROWTH INTL INCAFN.TOBefore Market OpenAir Transport Services Group, Inc.ATSGTime Not SuppliedListenAldila, Inc.ALDAAfter Market CloseALEO SOLAR AG...
Click here to read the whole Article (external link)

New Star Analyst Rankings for The Quigley Corporation

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...
Click here to read the whole Article (external link)

QUIGLEY CORP Files SEC form 10-Q, Quarterly Report

Management's Discussion and Analysis of Financial Condition and Results of Operations A preliminary analysis of the lack of adequate primary and secondary end point data indicates that the results may have been attributed to fewer than expected evaluable patients due to a shortage of drug and a high number of patients terminated early due to a lack of compliance with application and usage protocols. All required end of study regulatory and reporting documentation and procedures will be completed. The Company will continue to consider licensing, partnering or collaborative relationship opportunities to further the development and potential commercialization of the QR-333 candidate and other formulations. Ethical Pharmaceutical The current activity of the Company's wholly-owned subsidiary, Quigley Pharma Inc. ("Pharma"), is the research and development of potential natural base health products, including, but not limited to, prescription medicines along with supplements and cosmeceuticals for human and veterinary use. Research and development activities focus on the identification, isolation and direct use of active medicinal substances. One aspect of Pharma's research focus is on the potential synergistic benefits of combining isolated active constituents and whole plant components. The Company searches for new natural sources of medicinal substances from plants and fungi from around the world while also investigating the use of traditional and historic medicinals and therapeutics. Pharma is currently undergoing research and development activity in compliance with regulatory requirements. The Company is in the initial stages of what may be a lengthy process to develop its patent applications into commercial products. The Company has invested significantly in ongoing research and development activities. The pre-clinical development, clinical trials, product manufacturing and marketing of Pharma's potential new products are subject to federal and state regulation in the United Sta...
Click here to read the whole Article (external link)

QUIGLEY CORP Files SEC form 8-K/A, Financial Statements and Exhibits

Show all filings for QUIGLEY CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K/A for QUIGLEY CORP 12-Nov-2009Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for...
Click here to read the whole Article (external link)

QUIGLEY CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

Show all filings for QUIGLEY CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for QUIGLEY CORP 12-Nov-2009Results of Operations and Financial Condition, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is"...
Click here to read the whole Article (external link)